Pfizer has made the decision to discontinue the clinical development program for danuglipron, an oral GLP-1 receptor agonist, being investigated for chronic weight management.

In a study of adults with diabetes and gastrointestinal (GI) motility abnormalities, over 75% had GI motility abnormalities.